source
- Merck remains optimistic on Terns leukemia drug despite new dataMerck said Thursday that it still sees a compelling outlook for Terns' leukemia drug even after updated study data suggested it may be less differentiated. The updated data came from a trial of TE…
- UniQure to submit UK marketing application for Huntington's gene therapy AMT-130UniQure announced it will file a marketing application in the United Kingdom later this year for its gene therapy AMT-130 aimed at Huntington's disease. The filing follows a positive meeting with…